CL2021002632A1 - Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista - Google Patents
Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autistaInfo
- Publication number
- CL2021002632A1 CL2021002632A1 CL2021002632A CL2021002632A CL2021002632A1 CL 2021002632 A1 CL2021002632 A1 CL 2021002632A1 CL 2021002632 A CL2021002632 A CL 2021002632A CL 2021002632 A CL2021002632 A CL 2021002632A CL 2021002632 A1 CL2021002632 A1 CL 2021002632A1
- Authority
- CL
- Chile
- Prior art keywords
- disorder
- autism spectrum
- derivatives
- autism
- carbamoyl
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 4
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical class NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 title 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 abstract 3
- 201000007197 atypical autism Diseases 0.000 abstract 2
- 229960005123 cariprazine Drugs 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 230000001953 sensory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al compuesto de trans-N-[4-[2-[4-(2,3-diclorofenil)piperazin-1-il]etil]ciclohexil]-N’,N’-dimetilurea (cariprazina), sus sales, análogos cercanos, derivados, composiciones farmacéuticas, metabolitos y combinaciones para su uso en el tratamiento de los síntomas del trastorno del espectro autista en general, y preferentemente el objeto de la presente invención es tratar uno o más síntomas del autismo. Además, se determinó también que la cariprazina, sus sales, análogos cercanos, derivados, composiciones farmacéuticas, metabolitos y combinaciones son adecuadas para el tratamiento de afecciones tales como el síndrome de Asperger, autismo atípico (también conocido como trastorno generalizado del desarrollo no especificado de otra manera, TGD NE), el síndrome de Rett, el trastorno desintegrativo de la infancia, el trastorno por el déficit de atención e hiperactividad (TDAH) y la disfunción de integración sensorial.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1900121A HU231500B1 (hu) | 2019-04-10 | 2019-04-10 | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002632A1 true CL2021002632A1 (es) | 2022-05-06 |
Family
ID=89992883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002632A CL2021002632A1 (es) | 2019-04-10 | 2021-10-08 | Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3952872B1 (es) |
| JP (1) | JP2022527386A (es) |
| KR (1) | KR20210151162A (es) |
| CN (1) | CN113677345A (es) |
| AR (1) | AR118634A1 (es) |
| AU (1) | AU2020271363A1 (es) |
| BR (1) | BR112021019367A2 (es) |
| CL (1) | CL2021002632A1 (es) |
| DK (1) | DK3952872T3 (es) |
| EA (1) | EA202192717A1 (es) |
| FI (1) | FI3952872T3 (es) |
| GE (1) | GEP20237554B (es) |
| HU (1) | HU231500B1 (es) |
| IL (1) | IL287076A (es) |
| LT (1) | LT3952872T (es) |
| MX (1) | MX2021012321A (es) |
| PT (1) | PT3952872T (es) |
| SG (1) | SG11202110421YA (es) |
| TW (1) | TW202103701A (es) |
| UY (1) | UY38657A (es) |
| WO (1) | WO2020208564A1 (es) |
| ZA (1) | ZA202108429B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588162B (zh) * | 2022-03-30 | 2023-10-27 | 中国人民解放军空军军医大学 | 拉莫三嗪治疗孤独症触觉异常的应用 |
| US11980603B2 (en) | 2022-06-11 | 2024-05-14 | AMS Therapeutics, LLC | Method of treating expressive language deficit in autistic humans |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| HU230748B1 (hu) | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
| EP2155200B1 (en) | 2007-05-11 | 2016-12-07 | Richter Gedeon Nyrt. | Crystalline form of a carbamoyl-cyclohexane derivative |
| HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| DK2185155T3 (en) | 2007-08-03 | 2018-01-02 | Richter Gedeon Nyrt | PHARMACEUTICAL COMPOSITIONS WITH DOPAMINE RECEPTOR LIGANDS AND TREATMENT METHODS USING DOPAMINE RECEPTOR LIGANDS |
| SI2317852T1 (sl) | 2008-07-16 | 2015-04-30 | Richter Gedeon Nyrt. | Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja |
| US20110117214A1 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| HUE036035T2 (hu) | 2013-12-13 | 2018-06-28 | Pf Medicament | Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra |
-
2019
- 2019-04-10 HU HUP1900121A patent/HU231500B1/hu unknown
-
2020
- 2020-03-11 TW TW109108018A patent/TW202103701A/zh unknown
- 2020-04-08 AR ARP200101001A patent/AR118634A1/es unknown
- 2020-04-09 MX MX2021012321A patent/MX2021012321A/es unknown
- 2020-04-09 EA EA202192717A patent/EA202192717A1/ru unknown
- 2020-04-09 SG SG11202110421YA patent/SG11202110421YA/en unknown
- 2020-04-09 LT LTEPPCT/IB2020/053382T patent/LT3952872T/lt unknown
- 2020-04-09 AU AU2020271363A patent/AU2020271363A1/en active Pending
- 2020-04-09 GE GEAP202015793A patent/GEP20237554B/en unknown
- 2020-04-09 FI FIEP20719737.7T patent/FI3952872T3/fi active
- 2020-04-09 PT PT207197377T patent/PT3952872T/pt unknown
- 2020-04-09 WO PCT/IB2020/053382 patent/WO2020208564A1/en unknown
- 2020-04-09 EP EP20719737.7A patent/EP3952872B1/en active Active
- 2020-04-09 BR BR112021019367A patent/BR112021019367A2/pt unknown
- 2020-04-09 JP JP2021559605A patent/JP2022527386A/ja active Pending
- 2020-04-09 DK DK20719737.7T patent/DK3952872T3/da active
- 2020-04-09 CN CN202080027793.XA patent/CN113677345A/zh active Pending
- 2020-04-09 KR KR1020217036553A patent/KR20210151162A/ko active Search and Examination
- 2020-04-13 UY UY0001038657A patent/UY38657A/es unknown
-
2021
- 2021-10-07 IL IL287076A patent/IL287076A/en unknown
- 2021-10-08 CL CL2021002632A patent/CL2021002632A1/es unknown
- 2021-10-29 ZA ZA2021/08429A patent/ZA202108429B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527386A (ja) | 2022-06-01 |
| LT3952872T (lt) | 2024-05-27 |
| GEP20237554B (en) | 2023-10-25 |
| BR112021019367A2 (pt) | 2021-12-07 |
| IL287076A (en) | 2021-12-01 |
| FI3952872T3 (fi) | 2024-06-12 |
| EP3952872B1 (en) | 2024-03-13 |
| TW202103701A (zh) | 2021-02-01 |
| WO2020208564A1 (en) | 2020-10-15 |
| HUP1900121A1 (hu) | 2020-10-28 |
| HU231500B1 (hu) | 2024-04-28 |
| AU2020271363A1 (en) | 2021-11-18 |
| CN113677345A (zh) | 2021-11-19 |
| SG11202110421YA (en) | 2021-10-28 |
| AR118634A1 (es) | 2021-10-20 |
| PT3952872T (pt) | 2024-05-22 |
| EP3952872A1 (en) | 2022-02-16 |
| ZA202108429B (en) | 2022-09-28 |
| KR20210151162A (ko) | 2021-12-13 |
| MX2021012321A (es) | 2021-11-12 |
| UY38657A (es) | 2020-10-30 |
| DK3952872T3 (da) | 2024-05-27 |
| EA202192717A1 (ru) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002632A1 (es) | Derivados del carbamoil-ciclohexano para tratar el trastorno del espectro autista | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| CL2019001264A1 (es) | Ácidos propiónicos 3-sustituidos como inhibidores de la integrina alfa v. | |
| CO2020005459A2 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
| AR108301A1 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| CO6321264A2 (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de la pde9a | |
| ECSP22083904A (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| DOP2012000067A (es) | Compuestos de dióxido de iminotiadiazina como inhibidores de enzima de disociacion de app de sitio beta ( bace), composiciones, y su uso | |
| CL2011000306A1 (es) | Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion. | |
| EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
| CL2011000488A1 (es) | Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus. | |
| CU20110168A7 (es) | Derivados de benzofuranilo | |
| CR20180493A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CO2020005486A2 (es) | Compuestos espirocíclicos como moduladores del receptor farnesoide x | |
| ECSP21088111A (es) | Analogos de 3(5metil1,3tiazol2il)n{(1r)1[2(trifluormetil)pirimidin5il]etil}benzamida | |
| CL2021000424A1 (es) | Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| NI202000031A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| CL2012000013A1 (es) | Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer. | |
| BR112018004719A2 (pt) | composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto |